
iGUARD-Paraflu - An integrated Guided Ultrafast Antiviral RNAi inhalation Drug development against Parainfluenza infection

Consortium coordinator:

Prof. Dr. med., PhD Axel Schambach

*Institute of Experimental Hematology
Medizinische Hochschule Hannover*

Project partners:

Dr. Philippe Vollmer Barbosa

Fraunhofer Institute for Toxicology and Experimental Medicine

Prof. Dr. Armin Braun

*Division of Preclinical Pharmacology and Toxicology
Fraunhofer Institute for Toxicology and Experimental Medicine*

The goal of iGUARD-Paraflu consortium is to conduct important non-clinical studies that are essential for approval of clinical testing of the RNA inhalation drug iGUARD-01 directed against parainfluenza e.g. in immunocompromised individuals. These include formulation and stability studies of the drug candidate iGUARD-01 in preparation for a first Phase I clinical trial in humans embedded in a comprehensive regulatory strategy. Furthermore, a GMP manufacturing strategy for the drug product (the drug in its final form) will be developed and the cell entry mechanism for iGUARD-01 will be investigated in more detail. Finally, the commercialization potential of the drug will be analyzed and the obtained results will be comprehensively protected under patent law to enable further financing and clinical development of the drug.
